Bruxelles (Belgique) - 1er décembre 2022, 07h00 (CET): – UCB, une société biopharmaceutique mondiale, a annoncé aujourd'hui que les données de son portefeuille de médicaments antiépileptiques (brivaracétam, fenfluramine, lacosamide et midazolam en spray nasal) seront présentées lors du 76e congrès annuel de l'American Epilepsy Society (AES) (Nashville, Tennessee). ), du 2 au 6 décembre.
« UCB est à l'avant-garde de la recherche sur l'épilepsie depuis plus de trois décennies et nous sommes impatients de continuer à faire progresser la science et la compréhension de l'épilepsie, en particulier des épilepsies rares et de celles présentant d'importants besoins non satisfaits », a déclaré Konrad Werhahn, MD PhD, Global Epilepsy. Affaires médicales chez UCB. « Les données présentées cette année lors de la réunion annuelle de l'American Epilepsy Society continuent de renforcer notre engagement à redéfinir l'avenir des soins de l'épilepsie, en concevant des résultats thérapeutiques significatifs et axés sur le patient pour les personnes touchées par des crises d'épilepsie.
Faits saillants des données
Les données clés présentées à l'AES comprennent une multitude d'informations issues de l'étude internationale EXPERIENCE évaluant l'efficacité et la tolérabilité du brivaracétam dans plusieurs sous-populations, y compris les enfants et les personnes âgées souffrant de crises focales, ainsi que l'efficacité et l'innocuité de la fenfluramine sur les crises chez les personnes vivant avec des crises. avec les syndromes de Dravet et/ou de Lennox-Gastaut, et son impact sur les paramètres non convulsifs, y compris le fonctionnement exécutif quotidien. Présentation des données présentées dans l'exposition scientifique de la société, « UCB : Leading with science for epilepsy and rare epilepsy syndromes » (5 décembre, de 9h00 à 12h00 HE, au 207 A/B, étage 2, Music City Center) , offre aux professionnels de santé traitants l'occasion de participer à des discussions sur la recherche sur l'épilepsie d'UCB, les mises à jour concrètes et les dernières données cliniques.
Le symposium se concentre sur les questions clés liées aux données probantes du monde réel et à l'équité en santé
En complément des présentations par affiches, UCB organisera deux symposiums satellites pour les délégués inscrits à l'AES.
Brad Chapman, responsable de l'épilepsie et des syndromes rares aux États-Unis chez UCB, commente : « Alors qu'UCB continue d'élargir son portefeuille de médicaments contre l'épilepsie, les syndromes épileptiques rares et le traitement des crises, nous nous engageons à instaurer la confiance avec les communautés en continuant à écouter, à apprendre. , et évoluer dans la façon dont nous soignons et trouvons des solutions pour les patients.
Présentations par affiches
Ce qui suit est un guide des présentations d'affiches parrainées par UCB lors de la 76e réunion annuelle de l'American Epilepsy Society (AES 2022) :
Affiches Brivaracétam
Fenfluramine Affiches
Lacosamide Affiches
Spray nasal Midazolam [Approuvé par la FDA uniquement] Affiches
Affiches sur l’épilepsie générale
À propos de l’épilepsie1-3L'épilepsie est une maladie neurologique courante dans le monde et touche environ 50 millions de personnes.1 L'épilepsie et les convulsions peuvent se développer chez toute personne à tout âge2 et sont généralement diagnostiquées après qu'une personne a eu au moins deux crises (ou après une crise à haut risque). pour en savoir plus) qui n’étaient pas causées par une condition médicale connue.3
À propos d’UCB dans le traitement de l’épilepsie
UCB possède un riche héritage dans le domaine de l'épilepsie, avec trente ans d'expérience dans la recherche et le développement de médicaments antiépileptiques. En tant qu’entreprise engagée à long terme dans la recherche sur l’épilepsie, notre objectif est de répondre aux besoins médicaux non satisfaits. Nos scientifiques sont fiers de contribuer aux progrès de la compréhension de l’épilepsie et de son traitement. Nous établissons des partenariats et créons des super-réseaux avec des scientifiques et cliniciens de renommée mondiale travaillant dans des établissements universitaires, des sociétés pharmaceutiques et d'autres organisations qui partagent nos objectifs. Chez UCB, nous sommes inspirés par les patients et motivés par la science dans notre engagement à soutenir les patients épileptiques.
À propos d'UCB
UCB, Bruxelles, Belgique (www.ucb.com) est une société biopharmaceutique mondiale axée sur la découverte et le développement de médicaments et de solutions innovants pour transformer la vie des personnes atteintes de maladies graves du système immunitaire ou du système nerveux central. Avec plus de 8.600 collaborateurs dans environ 40 pays, UCB a généré un chiffre d'affaires de 5,8 milliards d'euros en 2021. UCB est cotée sur Euronext Bruxelles (symbole : UCB). Suivez-nous sur Twitter : @UCB_news
10% of patients) were somnolence (14.3%) and dizziness (11.0%). They were usually mild to moderate in intensity. Somnolence and fatigue were reported at higher incidences with increasing dose. Very common adverse reactions (≥1% to <10%) were influenza, decreased appetite, depression, anxiety, insomnia, irritability, convulsion, vertigo, upper respiratory tract infections, cough, nausea, vomiting, constipation and fatigue. Neutropenia has been reported in 0.5% (6/1,099) BRIVIACT® patients and 0% (0/459) placebo-treated patients. Four of these patients had decreased neutrophil counts at baseline, and experienced additional decrease in neutrophil counts after initiation of BRIVIACT®. None of the six cases were severe, required any specific treatment, led to BRIVIACT® discontinuation or had associated infections. Suicidal ideation was reported in 0.3 % (3/1099) of BRIVIACT® treated patients and 0.7 % (3/459) of placebo-treated patients. In short-term clinical studies of BRIVIACT® in patients with epilepsy, there were no cases of completed suicide and suicide attempt, however both were reported in the long-term open-label extension studies. Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of BRIVIACT® patients (9/3022) during clinical development. The safety profile of brivaracetam observed in children from 1 month of age was consistent with the safety profile observed in adults. In the open label, uncontrolled, long-term studies suicidal ideation was reported in 4.7 % of paediatric patients assessed from 6 years onwards (more common in adolescents) compared with 2.4 % of adults and behavioural disorders were reported in 24.8 % of paediatric patients compared with 15.1 % of adults. The majority of events were mild or moderate in intensity, were non-serious, and did not lead to discontinuation of study drug. An additional adverse reaction reported in children was psychomotor hyperactivity (4.7 %). No specific pattern of adverse event (AE) was identified in children from 1 month to < 4 years of age when compared to older paediatric age groups. No significant safety information was identified indicating the increasing incidence of a particular AE in this age group. As data available in children younger than 2 years of age are limited, brivaracetam is not indicated in this age range. No clinical data are available in neonates. strongOverdose /strongThere is limited clinical experience with BRIVIACT® overdose in humans. Somnolence and dizziness were reported in a healthy subject taking a single dose of 1,400 mg of BRIVIACT®. The following adverse reactions were reported with brivaracetam overdose: nausea, vertigo, balance disorder, anxiety, fatigue, irritability, aggression, insomnia, depression, and suicidal ideation in the post-marketing experience. In general, the adverse reactions associated with brivaracetam overdose were consistent with the known adverse reactions. There is no specific antidote. Treatment of an overdose should include general supportive measures. Since less than 10% of BRIVIACT® is excreted in urine, haemodialysis is not expected to significantly enhance BRIVIACT® clearance./p>
35mmHg)./p>
30 ml/min). In paediatric patients weighing 50 kg or more and in adult patients with mild or moderate renal impairment, a loading dose of 200 mg may be considered, but further dose titration (>200 mg daily) should be performed with caution. In paediatric patients weighing 50 kg or more and in adult patients with severe renal impairment (CLCR ≤ 30 ml/min) or with end-stage renal disease, a maximum dose of 250 mg/day is recommended and the dose titration should be performed with caution. In paediatric patients weighing less than 50 kg with severe renal impairment (CLCR ≤ 30 ml/min) and in those with end-stage renal disease, a reduction of 25 % of the maximum dose is recommended. A maximum dose of 300 mg/day is recommended for paediatric patients weighing 50 kg or more and for adult patients with mild to moderate hepatic impairment. Based on data in adults, in paediatric patients weighing less than 50 kg with mild to moderate hepatic impairment, a reduction of 25 % of the maximum dose should be applied. Lacosamide should be administered to adult and paediatric patients with severe hepatic impairment only when the expected therapeutic benefits are anticipated to outweigh the possible risks. The dose may need to be adjusted while carefully observing disease activity and potential side effects in the patient. In adolescents and adults weighing 50 kg or more with mild to moderate hepatic impairment a loading dose of 200mg may be considered, but further dose titration (>200 mg daily) should be performed with caution. Lacosamide is not recommended for use in children below the age of 4 years in the treatment of primary generalized tonic-clonic seizures and below the age of 2 years in the treatment of partial-onset seizures as there are limited data on safety and efficacy in these age groups. Contraindications: Hypersensitivity to the active substance or any of the excipients; known second- or third-degree atrioventricular (AV) block. Special warnings and precautions for use: Suicidal ideation and behaviour have been reported in patients treated with antiepileptic medicinal products in several indications. Therefore, patients should be monitored for signs of suicidal ideation and behaviour and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. Dose-related prolongations in PR interval with lacosamide have been observed in clinical studies. Lacosamide should be used with caution in patients with underlying proarrhythmic conditions such as known cardiac conduction problems or severe cardiac diseases (e.g. myocardial ischaemia/infarction, heart failure, structural heart disease or cardiac sodium channelopathies) or patients treated with medicinal products affecting cardiac conduction, including antiarrhythmics and sodium channel blocking antiepileptic medicinal products, as well as in elderly patients. In these patients it should be considered to perform an electrocardiogram (ECG) before a lacosamide dose increase above 400mg/day and after lacosamide is titrated to steady-state. In the placebo-controlled clinical studies of lacosamide in epilepsy patients, atrial fibrillation or flutter were not reported; however both have been reported in open-label epilepsy studies and in post-marketing experience. In post-marketing experience, AV block (including second degree or higher AV block) has been reported. In patients with proarrhythmic conditions, ventricular tachyarrhythmia has been reported. In rare cases, these events have led to asystole, cardiac arrest and death in patients with underlying proarrhythmic conditions. Patients should be made aware of the symptoms of cardiac arrhythmia (e.g. slow, rapid or irregular pulse, palpitations, shortness of breath, feeling lightheaded, fainting). Patients should be counselled to seek immediate medical advice if these symptoms occur. Treatment with lacosamide has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine. New onset or worsening of myoclonic seizures has been reported in both adult and paediatric patients with primary generalized tonic-clonic seizures (PGTCS), in particular during titration. In patients with more than one seizure type, the observed benefit of control for one seizure type should be weighed against any observed worsening in another seizure type. The safety and efficacy of lacosamide in paediatric patients with epilepsy syndromes in which focal and generalised seizures may coexist have not been determined. VIMPAT® syrup contains sodium methyl parahydroxybenzoate (E219) which may cause allergic reactions (possibly delayed). Vimpat Syrup contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine. Sorbitol may cause gastrointestinal discomfort and mild laxative effect. The syrup contains aspartame (E951), a source of phenylalanine, which may be harmful for people with phenylketonuria. Neither non-clinical nor clinical data are available to assess aspartame use in infants below 12 weeks of age. Vimpat syrup contains propylene glycol (E1520). VIMPAT® syrup contains 1.42 mg sodium per ml, equivalent to 0.07 % of the WHO recommended maximum daily intake of 2 g sodium for an adult. VIMPAT® solution for infusion contains 59.8 mg sodium per vial, equivalent to 3% of the WHO recommended maximum daily intake of 2 g sodium for an adult. Effects on ability to drive and use machines: Lacosamide may have minor to moderate influence on the ability to drive and use machines. Lacosamide treatment has been associated with dizziness or blurred vision. Accordingly, patients should be advised not to drive a car or to operate other potentially hazardous machinery until they are familiar with the effects of lacosamide on their ability to perform such activities. Undesirable effects: The most frequently reported adverse reactions (≥10%) are dizziness, headache, nausea and diplopia. They were usually mild to moderate in intensity. Some were dose-related and could be alleviated by reducing the dose. Incidence and severity of CNS and gastrointestinal (GI) adverse reactions usually decreased over time. Incidence of CNS adverse reactions such as dizziness may be higher after a loading dose. Other common adverse reactions (≥1% - <10%) are depression, confusional state, insomnia, balance disorder, myoclonic seizures, ataxia, memory impairment, cognitive disorder, somnolence, tremor, nystagmus, hypoesthesia, dysarthria, disturbance in attention, paraesthesia, vision blurred, vertigo, tinnitus, vomiting, constipation, flatulence, dyspepsia, dry mouth, diarrhoea, pruritus, rash, muscle spasms, gait disturbance, asthenia, fatigue, irritability, feeling drunk, injection site pain or discomfort (local adverse events associated with intravenous administration), irritation (local adverse events associated with intravenous administration), fall, and skin laceration and contusion. The use of lacosamide is associated with dose-related increase in the PR interval. Adverse reactions associated with PR interval prolongation (e.g. atrioventricular block, syncope, bradycardia) may occur. Multiorgan Hypersensitivity Reactions: Multiorgan hypersensitivity reactions (also known as Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS) have been reported in patients treated with some antiepileptic medicinal products. These reactions are variable in expression but typically present with fever and rash and can be associated with involvement of different organ systems. If multiorgan hypersensitivity reaction is suspected, lacosamide should be discontinued. The safety profile of lacosamide in adjunctive therapy in paediatric patients with partial- onset seizures was consistent with the safety profile observed in adults. The additional adverse reactions observed in the paediatric population were pyrexia, nasopharyngitis, pharyngitis, decreased appetite, abnormal behaviour and lethargy. Somnolence was reported more frequently in the paediatric population (≥ 1/10) compared to the adult population (≥ 1/100 to < 1/10).Refer to the European Summary of Product Characteristics for other adverse reactions and full prescribing information. Date of revision: October 2022. https://www.ema.europa.eu/en/documents/product-information/vimpat-epar-product-information_en.pdf/p>